CG'806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3.

被引：0
|
作者：
Zhang, Weiguo [1 ]
Zhang, Hongying [2 ]
Local, Andrea [2 ]
Rice, William G. [2 ]
Ly, Charlie J. [1 ]
Yu, Guopan [1 ]
Howell, Stephen B. [3 ]
Andreeff, Michael [1 ]
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Aptose Biosci, San Diego, CA USA
[3] UCSD Canc Ctr, La Jolla, CA USA
来源：
CLINICAL CANCER RESEARCH | 2017年 / 23卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
25
引用
收藏
页码：49 / 50
页数：2
相关论文
共 50 条
  • [41] The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML cells expressing a constitutively active FLT3.
    Spiekermann, K
    Dirschinger, RJ
    Schwab, R
    Faber, F
    Buske, C
    Schnittger, S
    Kelly, LM
    Gilliland, G
    Hiddemann, W
    BLOOD, 2002, 100 (11) : 34A - 34A
  • [42] A human anti-FLT3 antibody inhibits growth of leukemia expressing either wild-type or ITD-mutant FLT3 receptor.
    Li, YW
    Li, HL
    Wang, MN
    Lu, D
    Bassi, R
    Zhang, HF
    Ludwig, D
    Piloto, O
    Small, D
    Witte, L
    Zhu, ZP
    Hicklin, D
    BLOOD, 2003, 102 (11) : 66A - 66A
  • [43] Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML
    Wu, Shuangshuang
    Liu, Fangbing
    Gai, Yuqing
    Carter, Jenna
    Edwards, Holly
    Huttemann, Maik
    Wang, Guan
    Li, Chunhuai
    Taub, Jeffrey W.
    Wang, Yue
    Ge, Yubin
    LEUKEMIA RESEARCH, 2024, 144
  • [44] Differential Impact of Conditioning Intensity on Post-Transplant Outcome of FLT3 -Mutated and FLT3 Wild Type AML in First Remission, a Report from Taiwan Bone Marrow Transplant Registry (TBMTR)
    Yeh, Su-Peng
    Yao, Ming
    Tang, Jih-Luh
    Liu, Jin-Hwang
    Chiou, Tzeon-Jye
    Tan, Tran-Der
    Wang, Po-Nan
    Chen, Yeu-Chin
    Hwang, Wen-Li
    Wang, Ciyuan-Jheng
    Chen, Tsai-Yun
    Liu, Ta-Chih
    Yu, Ming-Sun
    Wang, Tso-Fu
    BLOOD, 2017, 130
  • [45] CG′806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells
    Zhang, Hongying
    Local, Andrea
    Benbatoul, Khalid
    Folger, Peter
    Sheng, Susan
    McLaughlin, Taryn
    Danilov, Alexey V.
    Kurtz, Stephen E.
    Tyner, Jeffrey W.
    Howell, Stephen
    Rice, William G.
    BLOOD, 2018, 132
  • [46] BRD4 antagonist-based therapy exerts lethal activity against FLT3 mutation expressing AML cells resistant to FLT3 tyrosine kinase inhibitors
    Rodriguez, Melissa
    Fiskus, Warren
    Sharma, Sunil
    Qi, Jun
    Schaub, Leasha J.
    Shah, Bhavin
    Devaraj, Santhana G. T.
    Liu, Ka
    Iyer, Swaminathan
    Bradner, James E.
    Bhalla, Kapil N.
    CANCER RESEARCH, 2014, 74 (19)
  • [47] Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia
    Minami, Y
    Yamamoto, K
    Kiyoi, H
    Ueda, R
    Saito, H
    Naoe, T
    BLOOD, 2003, 102 (08) : 2969 - 2975
  • [48] Identification of tyrosine residues of importance for survival signaling through the scaffolding protein Gab2 in both wild-type FLT3 and the FLT3-ITD
    Masson, Kristina
    Liu, Tao
    Sun, Jianmin
    Ronnstrand, Lars
    BLOOD, 2007, 110 (11) : 484A - 484A
  • [49] Bone Marrow Stromal Cells Protect Both FLT3-ITD and FLT3-WT Primary AML Cells from the Anti-Leukemic Activity of the FLT3 Inhibitor AC220
    Dos Santos, Cedric
    Ndikuyeze, Georges Habineza
    Nisssan, Michael
    Zhou, Chenghui
    Shan, Xiaochuan
    Perl, Alexander E.
    Carroll, Martin P.
    Danet-Desnoyers, Gwenn
    BLOOD, 2014, 124 (21)
  • [50] Shikonin exerts an anti-leukemia effect against FLT3-ITD mutated acute myeloid leukemia cells via targeting FLT3 tyrosine kinase and its downstream pathways
    Zhao, Mu-Nan
    Su, Long
    Song, Fei
    Wei, Zhi-Feng
    Qin, Tian-Xue
    Zhang, Yun-Wei
    Li, Wei
    Gao, Su-Jun
    ACTA HAEMATOLOGICA, 2023, : 310 - 323
12345